P53 (protein 53 kDa) by Hamelin, R & Huret, JL









Atlas Genet Cytogenet Oncol Haematol. 1999; 3(1)  
 
8 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
OPEN ACCESS JOURNAL AT INIST-CNRS 
P53 (Protein 53 kDa) 
Richard Hamelin, Jean-Loup Huret 
INSERM U434, Laboratoire de Genetique des Tumeurs, CEPH, Paris, France (RH), Genetics, Dept 
Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France (JLH) 
 
Published in Atlas Database: October 1998 
Online updated version : http://AtlasGeneticsOncology.org/Genes/P53ID88.html 
DOI: 10.4267/2042/37475 
This article is an update of: Hamelin R, Huret JL. P53 (protein 53 kDa). Atlas Genet Cytogenet Oncol Haematol.1998;2(4):119. 
 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 1999 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
 
Identity 




The gene encompasses 20 kb of DNA; 11 exons 
(the first is non-coding). 
Transcription 
3.0 kb mRNA; 1179 bp open reading frame. 
Protein 
Description 
393 amino acids; 53 kDa phosphoprotein; contains, 
from N-term to C-term, a transactivation domain, a 
DNA-binding domain, nuclear localization signals 






Tumour suppressor gene; P53 is a transcriptional 
regulator acting as a guardian of the genome; in 
response to DNA damage, p53 is overexpressed and 
activates the transcription of genes such as p21 
(implicated in cell-cycle arrest) and BAX 
(implicated in apoptosis); these activations allow 
either the cells to repair DNA damage before 
entering further in the cell cycle, or to be 
eliminated. In both cases, the consequence is to 
prevent propogation of cells containing genetic 
alterations. 
Homology 




In Li-Fraumeni syndrome, a dominantly inherited 
disease in which affected individuals are 
predisposed to develop sarcomas, osteosarcomas, 
leukemias and breast cancers at unusually early 
ages. 
Somatic 
P53 is mutated in about 50% of human cancers, and 
the non-mutated allele is generally lost; the 
frequency and the type of mutation may vary from 
one tumor type to another; in general, mutations are 
found in the central part (exons 4-8) of the p53 
gene; these mutations are missense, non-sense, 
deletions, insertions or splicing mutations; there a
some hot-spots for mutations at CpG dinucleotides 
at positions 175, 24 H8, 273 and 282; P53 mutation 
is an adverse prognostic feature in a number of 




Autosomal dominant condition; cancer prone 
disease; Li-Fraumeni syndrome is defined by the 
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existence of both a proband with a sarcoma and two 
other first-degree relatives with a cancer by age 45 
years; a mutation of P53 is found in at least 50% of 
cases; a percentage of mutations may be uncovered; 
a gene, upstream P53, could also be implicated in 
other cases with germline P53; therefore, 
heterogeneity is likely. 
Prognosis 
Most common cancer in Li-Fraumeni children are: 
soft tissues sarcoma before the age of 5 years and 
osteosarcoma afterwards, and breast cancer in 
young adults; other frequent cancers: brain 
tumours, leukaemias, adrenocortical carcinoma; 1/3 
of patients have developped more than one primary 
cancer, which is quite characteristic of Li-Fraumeni 
syndrome but may also be representative of Blooms 
syndrome; cancers in this disease, as in other 
cancer-prone diseases, often occur early in life: 
50% of patients aged 30 years have had a cancer 
(i.e. penetrance is 50%, according to this disease 
definition); and penetrance is 90% at age 60 years. 
Oncogenesis 
(Known) germinal mutation are variable, but are 
mostly missense mutations located in exons 5 to 8 
(DNA binding domain); in tumours occurring in 
these patients, the other (wildtype) allele is lost, in 
accordance with the two-hit model for neoplasia, as 
is found in retinoblastoma. 
Haematological malignancies 
Oncogenesis 
P53 gene alterations have been found in: 
- 20-30% of blast crisis CML (mostly in the 
myeloid type), often associated with i(17q); in  
- 5% of MDS cases and 15% of ANLL often with a 
visible del(17p); in  
- 2% of ALL (but with high variations according to 
the ALL type, reaching 50% of L3 ALL (and 
Burkitt lymphomas)); in  
- 15% of CLL (and 40% in the aggressive CLL 
transformation into the Richter's syndrome) and 
30% of adult T-cell leukiaemia (only found in the 
aggressive form); in  
- 5-10% of multiple myelomas; in  
- 60-80% of Hodgkin disease; in  
- 30% of high grade B-cell NHL (rare in low grade 
NHL), and 50% of HIV-related NHL;  
- P53 gene alterations in haematological  
malignancies are associated with a poor prognosis. 
Lung cancers 
Disease 
Lung cancers are neuroendocrine lung tumours 
(small cell lung carcinomas, carcinoids, large cell 
neuroendocrine carcinomas) or non neuroendocrine 
lung tumours (squamous carcinomas, 
adenocarcinomas, large cell carcinomas). 
Oncogenesis 
Is multistep, through C-MYC or N-MYC 
activation, H-RAS1 or K-RAS2 mutation, P53, 
RB1, and P16 inactivation, loss of heterozygosity 
(LOH) at 3p, 13q, 17p; P53 mutations, in this 
particular case, does not seem to have prognostic 
implication; P53 is mutated in 30% of lung 
adenocarcinomas to 80% of small cell lung 




There are two types of colorectal cancers, according 
to the ploidy:  
- the diploid form, RER+ (Replication Error+), 
sporadic, without loss of heterozygosity (LOH), 
with few mutations of p53 and APC, and right-
sided;  
- the polyploid form, RER-, with LOH (5q, 17p, 
18q), mutations in p53, and more often left-sided, 
they have a worse prognosis. 
Prognosis 
Survival, although improving, is not much more 
than 50% after 5 years. 
Cytogenetics 
Diploid tumours without frequent allelic losses; 
aneuploid tumours with numerous allelic losses; 
LOH on chromosomes 17 and 18 in more than 75% 
of cases; other chromosome arms losses in about 
50% of cases. 
Oncogenesis 
A number of genes are known to be implicated in 
tumour progression in colorectal cancers: APC, 
P53, KRAS2, mismatch repair genes (MMR genes); 
P53 is mutated in 60-65% of colorectal cancer 
cases; mutations of P53 are mostly located in exons 




Highly variable, according to the stage and the 
grade. 
Cytogenetics 
-9, -11 or del(11p), del(17p) and LOH at 17p, 
del(13q), frequent other LOH, aneuploidy, 
polyploidy, complex karyotypes. 
Oncogenesis 
Multi-step and largely unknown process; loss of 9q 
and P53 mutations would be early events; RB1, and 
P16 inactivation, EGFR overexpression, LOH at 
3p, 8p, 11p, 13q, 17p, 18q; P53 is mutated in 40-
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60% of bladder cancer cases; hotspot at codon 280; 
P53 mutations bear a prognostic implication. 
Breast cancer 
Oncogenesis 
P53 is mutated in 30% of breast cancers;  
preferentially observed in advanced and aggressive 
forms; probably a late event; hotspots at codons 
175, 248, and 273. 
Skin cancers 
Disease 
Skin cancers include basal cell carcinomas, 
squamous cell cercinomas, and melanomas. 
Prognosis 
Highly different prognosis according to the 
pathological group. 
Oncogenesis 
P53 is mutated in 40-60% of skin cancers; hotspots 
at codons 196, 248, 278. 
Oesophagus cancers 
Disease 
Two main forms: squamous cell carcinoma and 
adenocarcinoma. 
Oncogenesis 
P53 is mutated in 50% of oesophagus cancers (80% 
in squamous cell carcinoma); probably an early 
event; hotspots at codons 175, and 248. 
Liver cancer 
Cytogenetics 
Losses of 1p, 4q, 5p, 5q, 8q, 13q, 16p, 16q, and 17p 
in 20 to 50% of cases. 
Oncogenesis 
Specific mutation at codon 249 related to aflatoxin 
B1 dietary exposure; hot spots otherwise at codons 
249 and 273. 
To be noted 
Note 
As bove quoted, heterogeneity concerning the 
gene(s) mutated in Li-fraumeni is probable; on the 
other hand, germinal mutations of P53 have also 
been found in families where the criteria for the Li-
Fraumeni syndrome were not reached. 
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